MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process

    T. Tropea, J. Schulze, C. Destro, L. Heathers, B. Henry, JM. Talarico, C. Stanley, M. Mcguire Kuhl, E. Flagg, T. Foroud (Philadelphia, USA)

    Objective: The Parkinson Progression Markers Initiative (PPMI) is a multinational, longitudinal observational study that collects clinical, imaging, biologic, and genetic data from participants with or…
  • 2024 International Congress

    Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.

    R. Durcan, J. Rowe (Cambridge, United Kingdom)

    Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…
  • 2024 International Congress

    A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment

    N. Shanbhag, J. Padmanabhan, Z. Zhang, B. Harel, H. Jia, T. Kangarloo, W. Yin, A. Dowling, A. Laurenza, P. Khudyakov, K. Galinksy, R. Latzman, T. Simuni, D. Weintraub, F. Horak, C. Lustig, P. Maruff, A. Simen (Cambridge, USA)

    Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…
  • 2024 International Congress

    Clinical correlates of apathy in Parkinson´s disease

    J. Arena, L. Fiorentini, C. Obarrio, M. Merello (Buenos Aires, Argentina)

    Objective: To investigate the demographic and clinical correlates of apathy in a group of patients from a Movement Disorders clinic in Latin America. Background: Apathy…
  • 2024 International Congress

    Ibudilast, a Phosphodiesterase Inhibitor, Alleviates Huntington’s Disease Pathology through Neuroinflammation Modulation and Signaling Pathway Regulation in a Rat Model

    S. -, V. Parcha (Dehardun, India)

    Objective: This research aims to assess whether Ibudilast (IBD), a phosphodiesterase IV (PDE IV) inhibitor, can mitigate the damage induced by 3-nitropropionic acid (3-NP) in…
  • 2024 International Congress

    Prodromal RBD and the risk of cognitive impairment in Parkinson’s disease.

    A. Martinez-Nunez, H. Hutchinson, V. Lavu, Q. Yuan, J. Dwarampudi, J. Wong (Gainesvile, USA)

    Objective: To identify the impact of prodromal RBD in the incidence of cognitive impairment in patients with early PD. Background: The association between sleep disorders…
  • 2024 International Congress

    Comparing digital gait and turning measures from a prescribed gait test in the clinic/laboratory versus the same test at home in people with Parkinson’s disease

    V. Shah, C. Silva-Batista, P. Burgos, A. Ragothaman, P. Carlson-Kuhta, K. Sowalsky, F. Horak, M. Mancini (Portland, USA)

    Objective: We aim to compare the performance of the same prescribed walk test in the laboratory/clinic versus in the home. Background: With the advent of…
  • 2024 International Congress

    The Freezing of Gait Change of Direction (FOG-COD) Test: A Novel Measure to Predict Falls

    R. Hand, H. Smith (Philadelphia, USA)

    Objective: To examine the relationship between freezing of gait (FOG), falls history, and a novel clinical measure in persons with parkinsonism. Background: Freezing of gait…
  • 2024 International Congress

    Possible Sarcopenia and its Association with Physical Activity among Parkinson’s disease Patients

    APC. Loureiro, C. Moreira, J. Monteiro, N. Dias, LF. Moreira (Curitiba, Brazil)

    Objective: This study aimed to screen the prevalence of possible sarcopenia and its association with physical activity level in a sample of PD patients. Background:…
  • 2024 International Congress

    Response inhibition in patients with Lithium induced Tremor

    S. Banerjee, S. Choudhury, S. Majumdar, A. Bayen, P. Jakati, M. Baker, S. Baker, H. Kumar (KOLKATA, India)

    Objective: In the current study we explored the response inhibition paradigm through Stop Signal Reaction Time (SSRT) task in patients with lithium induced tremor. Background:…
  • « Previous Page
  • 1
  • …
  • 248
  • 249
  • 250
  • 251
  • 252
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley